Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 3Recruiting 2Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Endometrial Neoplasms 4Neoplasms 2Weight Loss 1Prosthesis Failure 1Nutrition Disorders 1Menorrhagia 1Leiomyoma 1Endometrial Hyperplasia 1Adrenocortical Carcinoma 1

Interventions

Blood Specimen Collection 38pembrolizumab 36Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 18Exercise 17Carboplatin 16Nivolumab 15atezolizumab 14Cisplatin 14Drug Therapy 13Paclitaxel 12Fluorouracil 12Cyclophosphamide 12Cetuximab 12Trastuzumab 10Leucovorin 10Docetaxel 10Dexamethasone 10Pemetrexed 9Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Megestrol Acetate × Clear all
NCT06979596 2026-05-13

OMAHA-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
250 enrolled
Tumor-Agnostic

Neoplasms

NCT06500234 2024-07-15

Nutrition Impact on Immunotherapy of Cancer

Qingdao Central Hospital

Phase 3 Recruiting
300 enrolled

Neoplasms, Nutrition Disorders, Prosthesis Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡